ACM
CRL icon

Arvin Capital Management’s Charles River Laboratories CRL Stock Holding History

Arvin Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-67,838
Closed -$14M – 34
2024
Q2 		$14M Buy
67,838
+18,157
+37% +$4.11M 4.42% 8
2024
Q1 		$13.5M Buy
49,681
+29,620
+148% +$7.07M 5.04% 7
2023
Q4 		$4.74M Buy
+20,061
New +$3.95M 2.09% 21

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
EC
Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Arvin Capital Management's CRL Position: Q3 2024 in Review

Arvin Capital Management sold out of Charles River Laboratories (CRL) in Q3 2024, closing a stake of 67,838 shares — an estimated $14M sold.

Arvin Capital Management first reported a position in CRL in Q4 2023 and held it in 3 quarters. The position peaked at $14M in Q2 2024. 628 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

  • Arvin Capital Management reported no remaining Charles River Laboratories position as of Q3 2024 after selling out during the quarter.
  • Arvin Capital Management sold 67,838 Charles River Laboratories shares in Q3 2024, an estimated $14M.
  • Arvin Capital Management first reported a position in Charles River Laboratories in Q4 2023 and held it in 3 quarters.
  • Arvin Capital Management's Charles River Laboratories position peaked at $14M in Q2 2024.
  • 628 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on Arvin Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.